Company: JUNS
Filing Date: 2025-10-17
Form Type: PRE 14A
Source: 0001493152-25-018523
Chunk: 63

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-10-17
Form: PRE 14A
Chunk 63
---
 Plan; provided, however, that no dividends or dividend equivalents will be payable in respect to outstanding options or SARS. Dividend equivalents may not be paid until and to the extent the underlying award vests or is exercised.

Deferrals of Awards

Our Compensation Committee may, to the extent permitted by law, require or allow participants to defer receipt of all or part of any cash or Shares subject to their award agreements on the terms of any deferred compensation plan of our company or other terms set by our Compensation Committee. Any such deferred compensation plan or other terms set by our Compensation Committee will be exempt from, or comply with the rules under section 409A of the Code.

Transferability of Awards

Options, SARs, unvested restricted stock, and other awards under the 2025 Plan may not be sold or otherwise transferred except in the event of a participant’s death to his or her designated beneficiary or by will or the laws of descent and distribution, unless otherwise determined by our Compensation Committee. Our Compensation Committee may permit awards other than “incentive stock options” to be transferred for no consideration.

| -38- |

Change of Control

In the event of a change of control of our company (as defined in the 2025 Plan), each outstanding award will be treated as our Compensation Committee determines, either by the terms of the award agreement or by resolution adopted by our Compensation Committee, including, without limitation, that the awards may be vested, assumed, replaced with substitute awards, cashed-out or terminated.

Changes in Capital

In the event of a change in our capital structure, such as a share dividend, share split or recapitalization, or a corporate transaction, such as a merger, consolidation, reorganization or spin-off, our Compensation Committee or our Board will make substitutions or adjustments that it deems appropriate and equitable to: (a) the aggregate number, class and kind of Shares or other securities reserved for issuance and delivery under the 2025 Plan, (b) the number, class and kind of Shares or other securities subject to outstanding awards; (c) the option exercise price, grant price or other price of securities subject to outstanding options, stock appreciation rights and, to the extent applicable, other awards; and (d) other value determinations applicable to outstanding awards. In the case of a corporate transaction, these adjustments may include, for example, (1) cancellation of outstanding awards in exchange for payments of cash and/or property; (2) substitution of other property (for example, stock of another company